Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 3/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 2/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495798 | 0.90 | SLC6A2 (0.58) | CD274SLC6A2SLC6A4HPGDSIKBKB | |
| SCHEMBL16495615 | 0.89 | HPGDS (0.61) | HTR2CMCHR1SLC6A2SLC6A4CHRM4 | |
| SCHEMBL16496153 | 0.86 | ADRA2A (0.60) | CD274HTR2CMCHR1SCN9AHPGDS | |
| SCHEMBL16496105 | 0.85 | ADRA2A (0.61) | CD274HTR2CMCHR1SCN9AHPGDS | |
| SCHEMBL16495965 | 0.83 | RAD52 (0.53) | SLC6A2SLC6A4HPGDSIKBKB | |
| SCHEMBL16495622 | 0.80 | MCHR1 (0.58) | CD274HTR2CMCHR1CHRM4HPGDS | |
| SCHEMBL1758383 | 0.80 | SCN9A (0.69) | CD274HTR2CMCHR1SCN9AADRA2A | |
| SCHEMBL16495519 | 0.78 | HPGDS (0.65) | HTR2CMCHR1SLC6A2SLC6A4HPGDS | |
| SCHEMBL16495401 | 0.78 | GABRA5 (0.49) | HTR2CMCHR1 | |
| SCHEMBL16496188 | 0.77 | NPC1 (0.56) | HTR2CMCHR1HPGDSADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | CD274 2948/4885HTR2C 3209/4885MCHR1 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.